Company Profile

I-Cordis LLC
Profile last edited on: 8/8/2020      CAGE: 827Q1      UEI: D2AUZ7D5DXJ1

Business Identifier: Immunomodulatory molecule to prevent and treat heart failure
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4362 West Pine Boulevard
Saint Louis, MO 63108
   (303) 829-8122
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

I-Cordis LLC has developed a immunomodulatory molecule to prevent and treat heart failure. The firm was spun out of Washington University research on immunomodulatory molecules that were both known to be safe in humans and proven to have cardioprotective effects in order to identify novel targets and tools to treat heart failure. This research effort led to both the identification of B lymphocytes as an innovative target to modulate the immune response in heart failure and to the identification of Pirfenidone as an ideal starting point to develop a safe and effective drug for this patient population.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $1,824,935
Project Title: Development of a novel immunomodulatory pyridone for the treatment of acute heart damage

Key People / Management

  Jennifer Baltz

Company News

There are no news available.